NEW ORLEANS—The risk of radiation-induced cancer from cardiac CT is substantially lower than previously reported for general populations, according to a poster presentation at the 2008 American Heart Association (AHA) Scientific Sessions this week.

Carestream Molecular Imaging, a division of Carestream Health, has begun providing custom conjugation services for its Kodak X-Sight Nanospheres and Large Stokes Shift Dyes. In addition, the firm has released two new gel imaging systems to advance its popular line of Kodak Gel Logic Systems for in vitro applications in life science research laboratories.

Cardinal Health, a provider of healthcare products and services, has reported that its 2009 first quarter net income fell 17 percent, despite revenue increases, as a result of write-downs and restructuring charges.

Characterized by relative maturity and sluggish growth, the global fluoroscopy and mobile C-arms market is forecasted to crawl to 9,600 units worth $1.3 billion in 2012, according to a report from market research firm Global Industry Analysts (GIA).

While the overall risk of sudden cardiac death following MI has declined significantly in the past 30 years, there is an increased risk for the first month after having an MI. The risk after 30 days decreases unless patients develop heart failure, according to a study in the Nov. 5 issue of Journal of the American Medical Association.

Vital Images, a provider of advanced visualization and analysis solutions, has reported a net loss for the 2008 third quarter, which ended Sept. 30, of $243,000, compared to a net income of $927,000 for the 2007 third quarter.

Compounding economic pressures created by declining reimbursement and crushing administrative burdens, operating costs rose faster than revenue in many medical group practices in 2007, according to the Medical Group Management Association (MGMA).

EPIX Pharmaceuticals, a MR contrast agent developer, is reducing its cost structure by decreasing its work force by approximately 23 percent, and narrowing the current focus of its research and development efforts, effective immediately.